A Phase 3 interventional study of rivaroxaban and uninterrupted vitamin K antagonist (VKA) in Atrial Fibrillation, sponsored by Janssen Scientific Affairs, LLC. Completed at 44 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-06.
Sponsored by Janssen Scientific Affairs, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing rivaroxaban in Atrial Fibrillation — 8 open to participants now, 9 under way, none of them phase 3. Rivaroxaban · Atrial Fibrillation.
Among the 45 studies testing rivaroxaban in Atrial Fibrillation, this one is the 20th largest by enrollment, is one of 4 that started in 2013, is one of 16 in phase 3, and was the 7th registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 960 are open to participants now.
Browse Atrial Fibrillation studies →8 of the 45 studies testing rivaroxaban in Atrial Fibrillation are open now, in 4 countries. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 22+
China National Center for Cardiovascular Diseases · Sites in China
Ages 70+
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19–89
Xijing Hospital · Sites in China
Ages 18+
Korea University Anam Hospital · Sites in Korea, Republic of
Ages 19–99
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 17 · Phase 4 19
First in 2004; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 253 is above the median of 150 across 2,476 interventional studies indexed under Atrial Fibrillation.
Median enrollment 150 across the 45 interventional studies. Of the 26 that completed or were terminated, 7 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 45 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Scientific Affairs, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Scientific Affairs, LLC is the lead sponsor of 41 studies on the registry; 2 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
71 studies in Atrial Fibrillation by Johnson & Johnson: 7 open now, 12 under way, 1 of them phase 3. Of 57 finished, 39 (68%) have results posted.
Among the 71 studies in Atrial Fibrillation by Johnson & Johnson, this one is the 19th largest by enrollment of the 58 interventional ones that give a count, is one of 6 that started in 2013, is one of 12 in phase 3, and was the 23rd registered.
Johnson & Johnson’s Atrial Fibrillation studies by the year they started, since 2003.
3 of the studies testing rivaroxaban in Atrial Fibrillation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06108414China National Center for Cardiovascular DiseasesLow-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation | 2026-12-31 |
| NCT05487950Assistance Publique - Hôpitaux de ParisRivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk | 2027-04-05 |
| NCT03129490Herlev and Gentofte HospitalThe Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation | 2027-10-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 45 studies testing rivaroxaban in Atrial Fibrillation, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 71 in Atrial Fibrillation:
This tab as a report to print or save as PDF → With an account.
The purpose of this exploratory study is to evaluate the safety of rivaroxaban and uninterrupted vitamin K antagonist (VKA) in adult participants with non-valvular atrial fibrillation (NVAF) who undergo catheter ablation as measured by post-procedure major bleeding events.
This is a randomized (participants are assigned to intervention groups by chance), open-label (both physicians and participants know the identity of the assigned treatment), active-controlled, multi-center safety study of rivaroxaban or VKA before and after a catheter ablation procedure. This study requires collaboration with medical institutions that provide access to electrophysiologists who normally perform the catheter ablation procedure. In this study, NVAF is to be defined as the presence of AF in a person who does not have a prosthetic heart valve (annuloplasty with or without prosthetic ring, commissurotomy and/or valvuloplasty are permitted) and who does not have hemodynamically significant mitral valve stenosis. Approximately 250 eligible participants, age 18 years or older, with a history of paroxysmal, persistent, or long standing persistent NVAF who are scheduled to undergo an elective catheter ablation procedure will be randomized in a 1:1 ratio to receive either rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal or VKA (adjusted to achieve a recommended International Normalized Ratio of 2.0 to 3.0).
The study will consist of a screening period, a pre-procedure period, procedure period and post-procedure period. The screening period will begin up to 2 weeks prior to randomization. Participants will be randomized at the beginning of the pre-procedure period. During this period, participants will be recommended to receive their assigned treatment for at least 4 weeks (maximum of 5 weeks) before the catheter ablation procedure. For participants with the sufficient anticoagulation, documented for the 3 weeks prior to randomization, and for participants with a transesophageal echocardiogram (TEE) or intracardiac echocardiography (ICE), the length of the pre-procedure period may be reduced down to 1-7 days and must include any transition from the previous anticoagulation therapy to randomized study drug.
After the catheter ablation procedure, participants will receive their post-procedure dose of study drug through a minimum of 30 + - 5 days. In addition to scheduled visits and telephone calls the study may also include additional phone calls and visits by the participant to the site when dose adjustment is required for usual care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal
Drug: rivaroxaban
dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0
Drug: uninterrupted vitamin K antagonist (VKA)
rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal
dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0
Number of Participants With Incidence of Post-Procedure Major Bleeding Events
Post-procedure major bleeding events include Thrombolysis in Myocardial Infarction (TIMI), International Society on Thrombosis and Haemostasis (ISTH) and Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Severe/life threatening bleeding.
Time frame: Up to 30 plus or minus (+-) 5 days after the catheter ablation procedure
Number of Participants With Composite Endpoint of Myocardial Infarction (MI), Ischemic Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism and Vascular Death
The composite endpoint include Myocardial Infarction (MI), Ischemic Stroke, Non-Central Nervous System (non-CNS) Systemic Embolism and Vascular Death.
Time frame: Up to 30 plus or minus (+-) 5 days after the catheter ablation procedure
Number of Participants With Myocardial Infarction (MI)
The MI was defined as clinical symptoms consistent with myocardial ischemia and cardiac biomarker elevation greater than the site's upper limit of normal (ULN) or development of new pathological Q waves in at least 2 contiguous leads on the electrocardiogram (ECG) or autopsy confirmation, OR Creatine kinase-muscle and brain subunit \[or creatine kinase (CK) in the absence of CK-MB\] greater than (\>) 3 or 5 or 10 x ULN for samples obtained within 24 hours of the procedure if the baseline values were normal or at least a 50 percent (%) increase over elevated baseline values that were stable or decreasing or development of new pathological Q waves in at least 2 contiguous leads on the electrocardiogram. Symptoms of cardiac ischemia were not required.
Time frame: Up to 30 plus or minus (+-) 5 days after the catheter ablation procedure
Number of Participants With Ischemic Stroke
Stroke was defined as a new, sudden, focal neurological deficit resulting from a presumed cerebrovascular cause that was not reversible within 24 hours and not due to a readily identifiable cause such as a tumor or seizure.
Time frame: Up to 30 plus or minus (+-) 5 days after the catheter ablation procedure
Number of Participants With Non-Central Nervous System (Non-CNS) Systemic Embolism
The Non-CNS systemic embolism was defined as abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms, (example; trauma, atherosclerosis, instrumentation).
Time frame: Up to 30 plus or minus (+-) 5 days after the catheter ablation procedure
Number of Participants With Vascular Death
Any death that was not clearly non-vascular. Examples of vascular death included deaths due to bleeding, Myocardial Infarction (MI), stroke, heart failure and arrhythmias.
Time frame: Up to 30 plus or minus (+-) 5 days after the catheter ablation procedure
Participants were randomized at 37 sites in 5 countries.
| Milestone | Rivaroxaban | Vitamin K Antagonist |
|---|---|---|
| Started | 124 | 124 |
| Completed | 112 | 101 |
| Not completed | 12 | 23 |
| Withdrew: Adverse event | 7 | 7 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 |
| Withdrew: Other | 4 | 9 |
Post-procedure major bleeding events include Thrombolysis in Myocardial Infarction (TIMI), International Society on Thrombosis and Haemostasis (ISTH) and Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Severe/life threatening bleeding.
| Participants | Rivaroxaban | Vitamin K Antagonist |
|---|---|---|
| TIMI Major Bleeding | 0 | 0 |
| ISTH Major Bleeding | 0 | 1 |
| GUSTO Severe/Life Threatening Bleeding | 0 | 0 |
The composite endpoint include Myocardial Infarction (MI), Ischemic Stroke, Non-Central Nervous System (non-CNS) Systemic Embolism and Vascular Death.
| Participants | Rivaroxaban | Vitamin K Antagonist |
|---|---|---|
| Number of Participants With Composite Endpoint of Myocardial Infarction (MI), Ischemic Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism and Vascular Death | 0 | 2 |
The MI was defined as clinical symptoms consistent with myocardial ischemia and cardiac biomarker elevation greater than the site's upper limit of normal (ULN) or development of new pathological Q waves in at least 2 contiguous leads on the electrocardiogram (ECG) or autopsy confirmation, OR Creatine kinase-muscle and brain subunit \[or creatine kinase (CK) in the absence of CK-MB\] greater than (\>) 3 or 5 or 10 x ULN for samples obtained within 24 hours of the procedure if the baseline values were normal or at least a 50 percent (%) increase over elevated baseline values that were stable or decreasing or development of new pathological Q waves in at least 2 contiguous leads on the electrocardiogram. Symptoms of cardiac ischemia were not required.
| Participants | Rivaroxaban | Vitamin K Antagonist |
|---|---|---|
| Number of Participants With Myocardial Infarction (MI) | 0 | 0 |
Stroke was defined as a new, sudden, focal neurological deficit resulting from a presumed cerebrovascular cause that was not reversible within 24 hours and not due to a readily identifiable cause such as a tumor or seizure.
| Participants | Rivaroxaban | Vitamin K Antagonist |
|---|---|---|
| Number of Participants With Ischemic Stroke | 0 | 1 |
The Non-CNS systemic embolism was defined as abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms, (example; trauma, atherosclerosis, instrumentation).
| Participants | Rivaroxaban | Vitamin K Antagonist |
|---|---|---|
| Number of Participants With Non-Central Nervous System (Non-CNS) Systemic Embolism | 0 | 0 |
Any death that was not clearly non-vascular. Examples of vascular death included deaths due to bleeding, Myocardial Infarction (MI), stroke, heart failure and arrhythmias.
| Participants | Rivaroxaban | Vitamin K Antagonist |
|---|---|---|
| Number of Participants With Vascular Death | 0 | 1 |
Collected over Screening up to Week 8-10. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rivaroxaban | — | 17/123 (13.8%) | 26/123 (21.1%) |
| Vitamin K Antagonist | — | 20/121 (16.5%) | 20/121 (16.5%) |
| Event | Rivaroxaban | Vitamin K Antagonist |
|---|---|---|
| Atrial fibrillationCardiac disorders | 3/123 | 5/121 |
| Vascular pseudoaneurysmInjury, poisoning and procedural complications | 2/123 | 2/121 |
| BradycardiaCardiac disorders | 2/123 | 0/121 |
| PyrexiaGeneral disorders | 2/123 | 0/121 |
| AnaemiaBlood and lymphatic system disorders | 0/123 | 1/121 |
| Acute myocardial infarctionCardiac disorders | 0/123 | 1/121 |
| Atrial tachycardiaCardiac disorders | 0/123 | 1/121 |
| Cardiac failureCardiac disorders | 0/123 | 1/121 |
| PericarditisCardiac disorders | 1/123 | 1/121 |
| Sinus arrestCardiac disorders | 0/123 | 1/121 |
| Event | Rivaroxaban | Vitamin K Antagonist |
|---|---|---|
| Atrial fibrillationCardiac disorders | 10/123 | 10/121 |
| HaematomaVascular disorders | 9/123 | 9/121 |
| FatigueGeneral disorders | 8/123 | 2/121 |
| Age, Continuous(years) | Rivaroxaban | Vitamin K Antagonist | Total |
|---|---|---|---|
| Mean | 58.6 ± 9.86 | 60.5 ± 10.51 | 59.5 ± 10.21 |
| Sex: Female, Male(Participants) | Rivaroxaban | Vitamin K Antagonist | Total |
|---|---|---|---|
| Female | 38 | 34 | 72 |
| Male | 86 | 90 | 176 |
| Region of Enrollment(participants) | Rivaroxaban | Vitamin K Antagonist | Total |
|---|---|---|---|
| Belgium | 24 | 24 | 48 |
| France | 19 | 19 | 38 |
| Germany | 18 | 19 | 37 |
| Great Britain | 24 | 24 | 48 |
| United States of America | 39 | 38 | 77 |
| Race(participants) | Rivaroxaban | Vitamin K Antagonist | Total |
|---|---|---|---|
| ASIAN | 5 | 2 | 7 |
| BLACK | 3 | 3 | 6 |
| N/A | 4 | 3 | 7 |
| WHITE | 112 | 116 | 228 |
| Ethnicity(participants) | Rivaroxaban | Vitamin K Antagonist | Total |
|---|---|---|---|
| HISPANIC/LATINO | 0 | 4 | 4 |
| N/A | 34 | 26 | 60 |
| NOT HISPANIC/LATINO | 90 | 94 | 184 |
| Body-Mass Index(kg/m^2) | Rivaroxaban | Vitamin K Antagonist | Total |
|---|---|---|---|
| Mean | 29.8 ± 5.74 | 28.9 ± 5.49 | 29.4 ± 5.62 |
| Diastolic Blood Pressure(mmHg) | Rivaroxaban | Vitamin K Antagonist | Total |
|---|---|---|---|
| Mean | 81 ± 9.85 | 79.4 ± 10.78 | 80.2 ± 10.34 |
| Systolic Blood Pressure(mmHg) | Rivaroxaban | Vitamin K Antagonist | Total |
|---|---|---|---|
| Mean | 133.3 ± 15.6 | 131.2 ± 17.68 | 132.2 ± 16.67 |
The record gives a start of Feb 2013, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban
Janssen Scientific Affairs, LLC →